A synonymous codon variant in two patients with autosomal recessive bestrophinopathy alters in vitro splicing of BEST1 by Davidson, Alice E. et al.
A synonymous codon variant in two patients with autosomal
recessive bestrophinopathy alters in vitro splicing of BEST1
Alice E. Davidson,1,3 Panagiotis I. Sergouniotis,3 Rosemary Burgess-Mullan,1 Nichola Hart-Holden,1
Sancy Low,2,3 Paul J. Foster,2,3 Forbes D.C. Manson,1 Graeme C.M. Black,1 Andrew R. Webster2,3
1School of Biomedicine, The University of Manchester, Manchester Academic Health Science Centre, Central Manchester University
Hospitals NHS Foundation Trust, Manchester, UK; 2Moorfields Eye Hospital, London, UK; 3Institute of Ophthalmology, University
College London, London, UK
Purpose: Autosomal recessive bestrophinopathy (ARB) is a newly defined retinal dystrophy caused by biallelic mutations
in bestrophin-1 (BEST1) and is hypothesized to represent the null bestrophin-1 phenotype in humans. The aim was to
determine whether a synonymous BEST1 variant, c.102C>T, identified in two unrelated ARB patients, alters pre-mRNA
splicing of the gene. Additionally a detailed phenotypic characterization of this distinctive condition is presented for both
patients.
Methods: BEST1 was analyzed by direct sequencing. Patients underwent standard ophthalmic assessment. In silico and
in vitro analysis using a minigene system was performed to assess whether a synonymous variant identified, c.102C>T
p.Gly34Gly, alters pre-mRNA splicing of BEST1.
Results: Both ARB patients harbored either proven  (patient 1;  c.102C>T p.Gly34Gly  and c.572T>C p.Leu191Pro)
or presumed (patient 2; c.102C>T p.Gly34Gly and c.1470_1471delCA, p.His490GlnfsX24) biallelic mutations in BEST1
and  were  found  to  have  phenotypes  consistent  with  ARB.  In  vitro  analysis  of  the  synonymous  variant,  c.102C>T
p.Gly34Gly, demonstrated  it  to  introduce a cryptic splice donor site 52 nucleotides upstream of the actual splice donor
site.
Conclusions: The novel BEST1 variant identified, c.102C>T p.Gly34Gly, alters pre-mRNA splicing in vitro and is
potentially pathogenic. In vivo this splicing variant is predicted to lead to the production of an mRNA transcript with a
premature termination codon (p.Glu35TrpfsX11) that is predicted to be degraded by NMD.
Autosomal recessive bestrophinopathy (ARB) is caused
by  biallelic  mutations  in  BEST1  [1].  BEST1  encodes
bestrophin-1, a transmembrane protein primarily expressed in
the basolateral membrane of the retinal pigmented epithelium
(RPE) [2]. Best vitelliform macular dystrophy (BVMD) [3]
and  autosomal  dominant  vitreoretinochoroidopathy
(ADVIRC) [4] are also associated with mutations in BEST1.
Although the functional role of bestrophin-1 within the RPE
remains  uncertain,  with  postulated  functions  as  a  Ca2+
activated Cl- channel [5], a regulator of voltage gated Ca2+
channels [6], or as a HCO3
– channel [7] the study of disease-
associated BEST1 variants has helped to elucidate pathogenic
mechanisms underlying the bestrophinopathies. BMVD [3]
and ADVRIC [4] are both hypothesized to arise from gain-of-
function mutations that exert a dominant negative effect of the
wild-type allele, whereas ARB is hypothesized to result from
biallelic functionally null mutations and thus represents the
null bestrophin-1 phenotype in humans [1,8,9].
Ten compound heterozygous or homozygous mutations
have been identified in seven families diagnosed with ARB
[1,8,9]. Affected individuals present with central vision loss,
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abnormal dark and light adapted full-field electroretinograms
(ERGs)  and  a  severely  reduced  electro-oculogram  (EOG)
light-rise that cannot be explained by the magnitude of the
ERG  abnormalities.  On  fundoscopy,  widespread  RPE
irregularity and small, pale subretinal deposits, more clearly
demonstrated  on  autofluorescence  (AF)  imaging,  are
observed. BEST1 expression is higher in the peripheral RPE
compared to the macular RPE [10]. A lack of bestrophin-1
across the entire RPE (null phenotype) may explain the more
widespread and progressive photoreceptor dysfunction and
the widespread punctuate flecks observed in the peripheral
retina in patients with ARB.
In this report we investigate how a synonymous BEST1
variant, identified in two unrelated patients with a clinical
diagnosis of ARB, affects pre-mRNA splicing, by performing
an ex vivo splice assay. The clinical phenotype is presented,
further establishing ARB as a distinctive bestrophinopathy.
METHODS
Study  subjects  and  clinical  examination:  Two  unrelated
patients  with  a  diagnosis  of  ARB  were  identified  in
Moorfields  Eye  Hospital,  London,  UK.  After  informed
consent  was  obtained,  blood  samples  were  donated  and
genomic  DNA  was  extracted  from  peripheral  blood
lymphocytes. The study was approved by the Moorfields and
Whittington Hospitals’ local ethics committee.
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2916Clinical assessment included: full medical history, best-
corrected Snellen visual acuity, dilated fundus examination,
color fundus photography, AF with a confocal scanning laser
ophthalmoscope (cSLO; HRA 2) and spectral-domain optical
coherence tomography (SD-OCT; Spectralis). EOG, ERG,
and pattern ERG procedures were performed according to the
International Society for Clinical Electrophysiology of Vision
(ISCEV) Standards [11-13]. Both patients were examined
more than twice over at least five years, making a longitudinal
evaluation of the phenotype possible.
DNA sequencing: All ten coding exons and flanking intronic
boundaries of BEST1 were analyzed by direct sequencing
from  PCR   amplicons  [1].  The  absence of  putative
BEST1    mutations   was    confirmed   by   single-stranded
conformation polymorphisms (SSCP) in 210 white European
control chromosomes [1]. The cDNA is numbered according
to Ensembl transcript ID ENST00000378043.
Ex vivo splice assay cloning: Due to the limited expression
pattern of BEST1 we could not evaluate the effect of c.102C>T
on splicing in patient-derived RNA. We therefore used an
alternative ex vivo splice assay approach. A plasmid encoding
a  wild-type  BEST1  fragment  was  generated  by  PCR
amplification from genomic DNA. The fragment was sub-
cloned into the α-globin–fibronectin–extra domain B (EDB)
minigene  [14].  The  c.102C>T,  p.Gly34Gly  variant  was
introduced  into  the  wild-type  construct  by  site-directed
mutagenesis  using  the  QuickChange  II  Kit  (Stratagene,
Cheshire, UK) in accordance with the manufacture’s protocol.
All constructs generated were sequenced to ensure fidelity and
orientation.
Figure 1. Color fundus photographs showing fundus autofluorescence (AF) imaging and horizontal spectral domain optical coherence
tomography (OCT) scans of affected individuals. A–C: patient 1 at 44 years of age; D–F: patient 2 at 45 years of age. Fundus pictures show
widespread retinal pigment epithelium (RPE) alterations and yellowish subretinal deposits along the vascular arcades as well as yellow-white
material in the maculae (A, D). Changes are more visible on AF imaging as diffuse, discrete areas of hyper and hypoautofluorescence (B,
E). On OCT, intraretinal or subretinal fluids as well as atrophy are shown (C, F).
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2917Ex  vivo  splice  assay:  Wild-type  and  mutant  (c.102C>T,
p.Gly34Gly)  EDB  minigene  constructs  were  transiently
transfected into HEK293 cells using Lipofectamine reagent
(Invitrogen, Paisley, UK). After 24 h, the cells were pelleted
and RNA was extracted using a QIA shredder kit (Qiagen,
Crawley, 
UK)  and  an  RNeasy  mini  kit  (Qiagen)  according  to  the
manufacturer’s  instructions.  After  DNase  treatment
(Promega, Hampshire, UK), cDNA was produced by reverse
transcription  (RT)  PCR  from  approximately  1  μg  RNA.
Vector-specific primers were used to establish cDNA linearity
loading controls for the experimental PCR assays.
RESULTS
Clinical findings: Subject 1, a 44-year-old female of white
European  origin  was  diagnosed  initially  with  macular
dystrophy at the age of 19 years. No family history of retinal
problems  was  reported.  She  was  first  noted  to  have  poor
central vision in a routine eye test at the age of nine. The
finding was predominant in the left eye and a diagnosis of
amblyopia was made. Bilateral YAG laser iridotomies were
performed at the age of 35 years, followed by trabeculectomy
and  vitrectomy  for  malignant  glaucoma  on  the  right  eye.
Pattern ERG performed at the age of 41 was undetectable on
the right and within normal limits on the left. Generalized
retinal  dysfunction  affecting  rod  more  than  cone
photoreceptors on full-field ERGs was recorded, and evidence
of  additional  dysfunction  affecting  the  photoreceptor/RPE
interface with a severely subnormal EOG light rise bilaterally
was observed. Humphrey field testing at age 41 demonstrated
significant field loss in the right eye. When examined at age
44, best-corrected visual acuities were 1.0 LogMAR in the
right  and  0.8  LogMAR  in  the  left  eye  with  a  hyperopic
correction (+3 D) on the right eye. The patient had glaucoma
and  was  being  treated  with  systemic  acetazolamide  and
topical treatment for glaucoma, with intraocular pressures
being  controlled.  Anterior  segment  OCT  imaging  showed
angle  closure  in  both  eyes.  Fundoscopy  showed  chronic
cystoid  macular  edema  on  the  right  and  pale  confluent
deposits  in  the  fovea  and  midperiphery  of  both  eyes.
Interestingly,  bilateral  nasal  juxtapapillary  drusen  were
observed (Figure 1A) and the patient was therefore screened
and  excluded  for  the  c.245C>T  p.Arg345Trp  mutation  in
EFEMP1.  Fundus  photographs,  autofluorescence  imaging
and spectral domain OCTs are shown in Figure 1A-C.
Subject  2,  a  45-year-old  white  European  male,  was
diagnosed initially with Stargardt macular dystrophy at 11
years and with narrow angle glaucoma at 21. The patient has
no family history of ocular disease. His two young children
have been reported to have normal vision. Problems with
central vision were first noted in early childhood and gradual
deterioration over the years was reported. Bilateral YAG laser
iridotomies  were  performed  at  the  age  of  22.
Electrophysiology performed at the age of 40 showed only
residual activity in pattern ERG. Full-field ERGs were in
keeping with generalized retinal dysfunction involving the
cone  and  rod  systems.  When  examined  at  age  44,  best-
corrected visual acuities were 1.0 LogMAR for the right and
0.8 LogMAR for the left eye. IOPs were controlled with
systemic and topical treatment for glaucoma. Fundoscopy
showed atrophic lesions in both maculae with small yellowish
subretinal  deposits  in  the  fovea  and  around  the  vascular
arcades  (Figure  1D).  The  changes  are  better  visible  on
autofluorescence imaging (Figure 1E). Spectral domain OCT
showed subretinal fluid between RPE and neurosensory retina
in the right and atrophic changes in the left macula (Figure
1F). Clinical details of subjects 1 and 2 are summarized in
Table 1.
Molecular findings and in silico analysis: Sequencing all the
coding  exons  of  BEST1  in  patient  1  identified  two  novel
heterozygous variants: c.102C>T p.Gly34Gly and c.572T>C
p.Leu191Pro.  The  proband’s  asymptomatic  son  was
subsequently  found  to  harbor  only  the  latter  variant,
confirming  that  the  changes  were  in  trans.  A  multiple
alignment of bestrophin-1 shows that the leucine residue at
position 191 is highly conserved down to Danio rerio (data
not  shown).  Patient  2  was  found  to  have  compound
heterozygous  mutations,  comprising  both  the  previously
reported  frame-shift  mutation,  c.1470_1471delCA,
p.His490GlnfsX24  [15]  and  the  novel  variant,  c.102C>T,
p.Gly34Gly.  The  novel  BEST1  variants  (c.102C>T
p.Gly34Gly and c.572T>C p.Leu191Pro) were absent in 210
white European control chromosomes tested.
To predict whether the c.102C>T p.G34G variant affects
exonic splice regulatory sequences and/or generates a cryptic
splice site within BEST1, the wild-type and mutated sequences
of exon 2 were analyzed using pre-mRNA splicing prediction
programs.  The  RESCUEese  website  [16]  predicts  that  no
exonic splice enhancer (ESE) sites are present in either the
wild-type or mutant sequence. The PeSX website [17,18]
predicts that the wild-type sequence contains an ESE which
is abolished in the mutant sequence. The ESE finder website
[19] predicts that the mutation abolishes an SRp55 binding
site  present  in  the  wild-type  sequence.  The  FAS-ESS
website [20] predicts that no exonic splice silencers (ESS)
sites are present in either the wild-type or mutant sequence.
Splice site prediction tools, Human Splicing Finder (HSF)
[21], NNSPLICE [22] and NetGene2 [23] all predict that the
variant may create a cryptic splice donor site 52 nucleotides
upstream of the genuine splice donor site.
Ex  vivo  α-globin-fibronectin-EDB  splice  assay:  To  test
whether  the  BEST1  variant  c.102C>T  affects  pre-mRNA
splicing, an ex vivo splice assay was performed. Wild-type
and  mutant  (c.102C>T  p.Gly34Gly)  sequences  of  BEST1
exon 2 and the surrounding intronic regions were cloned into
the  α-globin-fibronectin-EDB  splice  assay  vector  and
transfected into HEK 293 cells. Assays were performed as
previously described [14].
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2919Analysis of the resulting splice products demonstrated
that the wild-type and mutant constructs produced differently-
spliced  products  (Figure  2).  The  wild-type  construct  was
spliced to produce two products at approximately 480 bp and
250 bp, corresponding respectively to the vector exons spliced
to BEST1 exon 2, and the vector exons alone. It is notable that
wild-type exon 2 is only weakly spliced. This result can most
likely be attributed to the fact that we are not studying the exon
within its native genomic context, a disadvantage of all in vitro
splice assays. By contrast, the mutant construct was spliced to
produce two products at approximately 430 bp and 250 bp,
corresponding respectively to the vector exons spliced to a
truncated version of BEST1 exon 2 and the vector exons alone.
The mutant product appeared to be spliced more efficiently
than the wild-type product, suggesting that the cryptic splice
site introduced by the variant had a very strong effect on
splicing in this system. The identity of all alternatively spliced
products  was  established  by  direct  sequencing  and
demonstrated  that  the  c.102C>T  variant  creates  a  cryptic
splice donor site 52 nucleotides upstream of the genuine splice
donor  site,  supporting  the  predictions  made  by  the  splice
prediction tools HSF, NNSPLICE, and NetGene2 [21-23].
DISCUSSION
Since the first description of ARB as a novel retinal dystrophy
caused by bialleic mutations in BEST1, our understanding of
the clinical presentation and pathophysiology of the condition
has progressed [1,8,9]. The two unrelated probands reported
here both displayed key clinical features of the condition,
including loss of central vision in early in life, angle-closure
glaucoma, subretinal and intraretinal fluid accumulation, a
lack  of  a  dominant  mode  of  inheritance,  and  abnormal
electrophysiology (ERG and EOG light rise). Both patients
presented with recessive macular dystrophy in their second
decade of life and later developed glaucoma. This finding is
concordant with our previous study in which all ARB patients
described were found to be hyperopic and 3/7 patients were
also diagnosed with angle-closure glaucoma [1]. Importantly
for both probands in this study, the angle-closure glaucoma
contributed to visual loss, and we therefore recommend that
all  ARB  patients  be  routinely  screened  for  angle-closure
disease and associated glaucoma once diagnosed with the
condition. BEST1’s role within ocular development is poorly
understood. In the light of our current finding that ARB is
frequently associated with angle-closure glaucoma and that
Figure 2. The ex vivo splicing assay. A: Schematic representation of the α-globin-fibronectin- extra domain B (EDB) splice assay construct.
Wild-type and mutant (c.102C>T) forms of BEST1 exon 2 with flanking intronic sequence were cloned into the α-globin-fibronectin-EDB
splice assay vector. The position of the mutated residue is highlighted with a star, and primer binding sites to exonic vector sequences are
indicated with arrows. B: Splicing products generated by RT–PCR were separated by agarose gel electrophoresis as indicated. The identity
of the spliced products was established by direct sequencing and is schematically represented on the right. C: Agarose gel of RT–PCR reactions
performed with control primers designed against the vector sequence (dashed arrows in A) demonstrates equal loading of the cDNA template.
The figure represents results obtained from three separate experiments.
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2920BEST1 mutations cause the developmental ocular disorder
ADVIRC  [4],  we  believe  the  role  of  BEST1  in  ocular
development and glaucoma merits further investigation.
Patient  1  was  found  to  have  one  previously  reported
missense  change  and  one  novel  synonymous  variant  in
BEST1 (c.102C>T p.Gly34Gly and c.572T>C, p.Leu191Pro).
The proband’s asymptomatic son was subsequently found to
harbor only the latter variant, confirming that the changes
were in trans. Patient 2 had one frame-shift mutation and the
same  synonymous  variant  in  BEST1  as  patient  1  (c.
1470_1471delCA  p.His490GlnfsX24  and  c.102C>T
p.Gly34Gly). It was not possible to determine if the mutations
identified in patient 2 were in cis or trans as no familial DNA
samples were available for segregation analysis. However, the
phenotypic presentation of patient 2 is in keeping with ARB
and not BVMD. As ARB is caused by biallelic mutations in
BEST1 [1], a second pathogenic variant in trans to the c.
1470_1471delCA variant was likely. The in silico and in vitro
data  presented  support  the  belief  that  the  c.102C>T
p.Gly34Gly variant is likely to be pathogenic, and hence the
second disease causing allele in the patient. We therefore
hypothesize, based on the circumstantial evidence presented,
that the c.102C>T variant identified in patient 2 is pathogenic
and in trans to c.1470_1471delCA. A more parsimonious, but
not  impossible  interpretation  of  these  data  are  that  the  c.
102C>T p.Gly34Gly variant is benign, has by chance only
ever been found in these two phenotypically similar patients
and  that  both  have  unusual  manifestations  of  dominant
disease.
We hypothesized that the c.102C>T p.Gly34Gly variant,
located at the 3′ end of the first translated exon of BEST1, is
pathogenic by altering the pre-mRNA splicing. An in vitro
splice assay demonstrated the introduction of a cryptic splice
donor site 52 nucleotides upstream of the actual splice donor
site. Therefore, in vivo the synonymous variant is predicted
to  lead  to  the  production  of  an  mRNA  transcript  with  a
premature  stop  codon  (p.Glu35TrpfsX11)  that  would  be
presumed  to  be  degraded  by  nonsense-mediated  decay
(NMD). Previously we have suggested that ARB represents
the null bestophin-1 phenotype in humans, as patients with
biallelic  null  mutations  have  similar  phenotypic
characteristics  to  patients  with  compound  heterozygous
missense mutations in BEST1. The mutations identified here
in two further patients support this proposition. In patient 2
both  variants,  which  we  presume  to  be  in  trans,  produce
transcripts  that  are  predicated  to  be  degraded  by  NMD;
p.His490GlnfsX24  and  p.Glu35TrpfsX11.  Patient  1  has  a
similar phenotype to patient 2 and other ARB patients. This
suggests that the missense isoform in patient 1 lacks sufficient
function,  and  that  in  conjunction  with  the  second  allele
transcript that is predicted to be degraded by NMD, the patient
is functionally null for bestrophin-1.
Examples of synonymous exonic mutations introducing
cryptic splice donor sites have previously been reported [24,
25].  However  the  potential  for  such  synonymous  codon
changes  to  have  pathogenic  consequences  are  often
overlooked due to the strong association of exonic mutations
with solely protein coding changes. The work presented here
demonstrates the power of combining detailed phenotypic
analysis with comprehensive in silico and in vitro analysis of
a synonymous variant to facilitate an informed and accurate
diagnosis. With the ever-advancing pace of high throughput
DNA sequencing technologies, determining the relevance of
such  synonymous  variants  is  becoming  increasingly
important.
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